SCHEMBL5115232

SCHEMBL5115232

C#Cc1ccsc1-c1nc2cnccn2c1N(C)C.c1cc2cc-2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 13/20 0.38
MAPT P10636 9/20 0.38
KDM4E B2RXH2 5/20 0.36
LMNA P02545 2/20 0.36
MAPK1 P28482 1/20 0.36
TP53 P04637 2/20 0.36
RXFP1 Q9HBX9 2/20 0.36
BRAF P15056 2/20 0.35
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33
TUBB4B P68371 1/20 0.33
TUBB3 Q13509 1/20 0.33
TUBB2A Q13885 1/20 0.33
TUBB8 Q3ZCM7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5113515 0.85 GAA (0.41) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5121150 0.85 BRAF (0.36) GAAMAPTKDM4ELMNAMAPK1
Hydrochloric Acid SCHEMBL5121363 0.84 BRAF (0.36) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5115533 0.83 GAA (0.38) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5118759 0.82 CDK9 (0.41) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5127406 0.82 SALL4 (0.46) GAAKDM4ELMNAMAPK1BRAF
SCHEMBL5129311 0.81 PLAU (0.42) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5114310 0.80 SYK (0.40) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5121032 0.79 CDK9 (0.41) GAAMAPTKDM4ELMNAMAPK1
SCHEMBL5128033 0.79 BRD4 (0.48) GAAMAPTKDM4ELMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1791840-B1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH (DE) 2013-11-27 EP claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US claimed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US claimed
US-7420056-B2 Substituted bicyclic imidazo-3-ylamine compounds GRUENENTHAL GMBH (DE) 2008-09-02 US disclosed
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS GRUENENTHAL GMBH. (DE) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155965-A1 SUBSTITUTED BICYCLIC IMIDAZO-3-YLAMINE COMPOUNDS AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS GAA 234/4885MAPT 707/4885KDM4E 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.